miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

Non-small-cell lung cancer (NSCLC) is the most common malignancy worldwide. Platinum-based chemotherapy is the standard of care for these patients. Recent research showed that miR-7 methylation status is a biomarker of cisplatin resistance in lung and ovarian cancer cells, which is one of the major...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Biosci
Hauptverfasser: Rodríguez-Antolín, Carlos, Felguera-Selas, Laura, Pernía, Olga, Vera, Olga, Esteban, Isabel, Losantos García, Itsaso, de Castro, Javier, Rosas-Alonso, Rocío, Ibanez de Caceres, Inmaculada
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Letter to the Editor
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6686393/
https://ncbi.nlm.nih.gov/pubmed/31406565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0326-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge